Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs

Cancer Science
Kei-ichi OzakiMichiaki Kohno

Abstract

Although DNA-damaging agents are among the most effective anticancer drugs in clinical use, their overall effectiveness is limited by the development of cross-resistance to these drugs. Given that histone deacetylase (HDAC) inhibitors increase the acetylation of core histones, resulting in an open chromatin configuration that is more accessible to DNA-targeting agents, we examined whether HDAC inhibitors might enhance the cytotoxicity of DNA-damaging drugs in six human ovarian tumor cell lines that exhibit different cisplatin sensitivities. Low concentrations of HDAC inhibitors, which alone exhibited little cytotoxicity, markedly enhanced the induction of apoptotic cell death not only by cisplatin but also by a wide variety of DNA-targeting anticancer drugs in these tumor cell lines, irrespective of their sensitivities to the respective drugs. In contrast, HDAC inhibitors did not increase the cytotoxicity of metabolic antagonists or microtubule-targeting agents. HDAC inhibitors potentiated both the phosphorylation of histone H2AX on serine-139 (a marker of DNA double-strand breaks) as well as the accumulation of reactive oxygen species induced by DNA-damaging agents in tumor cells. The enhanced generation of reactive oxygen spe...Continue Reading

References

Mar 15, 1990·International Journal of Cancer. Journal International Du Cancer·R J SchilderT C Hamilton
Apr 16, 1998·The Journal of Biological Chemistry·E P RogakouW M Bonner
Oct 22, 1998·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M H Kuo, C D Allis
Jan 20, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R P Perez
Mar 21, 2002·Nature Reviews. Cancer·P MarksW K Kelly
May 7, 2002·Nature Reviews. Cancer·Laurence H Hurley
Jul 18, 2002·Nature Reviews. Drug Discovery·Ricky W Johnstone
Jan 21, 2004·Nature Reviews. Cancer·Andrew P Feinberg, Benjamin Tycko
May 18, 2004·Cancer Cell·Ping ZhuMartin Göttlicher
Aug 26, 2004·Advances in Cancer Research·Paul A MarksWilliam Kevin Kelly
Oct 7, 2004·Genes & Development·Anders H Lund, Maarten van Lohuizen
Dec 4, 2004·International Journal of Cancer. Journal International Du Cancer·Kevin CamphausenPhilip J Tofilon
May 10, 2005·Experimental Cell Research·Myoung Sook KimFrance Carrier
Dec 1, 2005·Journal of Cell Science·Sabine M GörischKarsten Rippe
Dec 13, 2005·Biochemical and Biophysical Research Communications·Kei-ichi OzakiMichiaki Kohno
Dec 28, 2005·Biochemical and Biophysical Research Communications·Yusuke FujiwaraMichiaki Kohno
Jan 7, 2006·Nature Reviews. Cancer·Saverio Minucci, Pier Giuseppe Pelicci
Mar 29, 2006·Virchows Archiv : an International Journal of Pathology·Paolo PiacentiniAldo Scarpa
Aug 4, 2006·Molecular Cell·Alison L ClaytonLouis C Mahadevan
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Mar 7, 2007·Nature Reviews. Genetics·Manel Esteller

❮ Previous
Next ❯

Citations

Apr 7, 2010·Cancer Chemotherapy and Pharmacology·Ilaria ZanellatoDomenico Osella
May 18, 2010·Wiener medizinische Wochenschrift·Rupert BartschGuenther G Steger
Sep 29, 2011·Oxidative Medicine and Cellular Longevity·Barbora Brodská, Aleš Holoubek
Aug 23, 2011·Cancer Cell International·Johanne I WeberpalsJim Dimitroulakos
Feb 26, 2010·Journal of Oncology·Katherine V Clark-KnowlesJohanne I Weberpals
May 31, 2014·Cell Death & Disease·L GalluzziG Kroemer
Apr 12, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·You ZhouZhi-Qiang Ning
Mar 18, 2011·Women's Health·Anastasia Pazaiti, Ian S Fentiman
Mar 19, 2011·Clinical and Experimental Nephrology·Yukitoshi SakaoAkira Hishida
Aug 26, 2010·Expert Review of Anticancer Therapy·Anastasia ConstantinidouJorge S Reis-Filho
Oct 4, 2012·Cancer Letters·Himashinie V K DiyabalanageJacob M Hooker
Jun 19, 2012·Journal of Pediatric Surgery·Timothy B LautzMary Beth Madonna
Nov 29, 2011·Biochemical Pharmacology·Paola PeregoFranco Zunino
Nov 15, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·William J Irvin, Lisa A Carey
Jul 19, 2008·Cancer Letters·Grégory Eot-HoullierChristian Jaulin
Nov 3, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Lubna Wasim, Madhu Chopra
Apr 21, 2018·Future Medicinal Chemistry·Zdeněk KejíkVladimír Král
Nov 13, 2015·Journal of Cancer Research and Clinical Oncology·Dmitri PchejetskiLeonardo Monzon
Jan 17, 2012·Clinical Epigenetics·Praveen RajendranRoderick H Dashwood
Aug 14, 2009·International Journal of Cancer. Journal International Du Cancer·Valentina ZucoFranco Zunino
Sep 10, 2016·Oncotarget·Brad Rybinski, Kyuson Yun
Feb 11, 2016·American Journal of Physiology. Endocrinology and Metabolism·Kei-Ichi OzakiMichiaki Kohno
May 8, 2018·Medicinal Research Reviews·Heba M HeshamKhaled A M Abouzid

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
J-H LeePaul A Marks
Nature Reviews. Drug Discovery
Jessica E BoldenR W Johnstone
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Michael Bots, R W Johnstone
© 2021 Meta ULC. All rights reserved